Patterson Companies, Inc. PDCO reported adjusted earnings per share (EPS) of 33 cents in first-quarter fiscal 2021, which beat the Zacks Consensus Estimate by 50%. Moreover, the bottom line improved 22.2% from the prior-year quarter. The improvement can be attributed to the benefit of temporary COVID-19 related expense savings and sequentially improving sales during the quarter under review.
Net sales in the quarter were $1.25 billion, outpacing the Zacks Consensus Estimate by 4.8%. However, the top line declined 6.2% year over year.
The company currently distributes products through subsidiaries — Patterson Dental and Patterson Animal Health.
This segment provides a complete range of consumable dental products, equipment, software, turnkey digital solutions and value-added services to dentists, and laboratories throughout North America.
In the fiscal first quarter, dental sales fell 14.1% year over year to $430.3 million.
Sales in the sub-segment totaled $256.6 million, down 15.4% year over year.
Dental Equipment & Software
Sales in the segment declined 10.1% on a year-over-year basis to $112.9 million.
Patterson Companies, Inc. Price, Consensus and EPS Surprise
Patterson Companies, Inc. price-consensus-eps-surprise-chart | Patterson Companies, Inc. Quote
This segment comprises technical service, parts and labor, software support services and office supplies. Sales at the segment declined 15.6% on a year-over-year basis to $60.7 million.
Animal Health Segment
This segment is a leading distributor of veterinary supplies to clinics, public and private institutions and shelters across the United States.
In the fiscal first quarter, the segment sales dipped 0.7% on a year-over-year basis to $812.2 million.
Sales at the segment were $3.4 million, which plunged 66% from $9.9 million in the year-ago quarter.
Gross profit in the reported quarter was $253.8 million, down 12.5% year over year. As a percentage of revenues, gross margin of 20.4% contracted 140 basis points (bps) on a year-over-year basis.
Operating expenses in the reported quarter totaled $215.9 million, declining 21% from the year-ago quarter.
The company reported operating income of $37.9 million, up 127.1% from the prior-year quarter. As a percentage of revenues, operating margin of 3% expanded 170 bps on a year-over-year basis.
The company exited the fiscal first quarter with cash and cash equivalents of $119.6 million, up 53.4% on a sequential basis.
Net cash used in operating activities in the fiscal first quarter were $229.8 million, wider than the year-ago quarter’s net cash utilized in operating activities of $45.2 million.
Fiscal 2021 Guidance
Patterson Companies refrained from issuing fiscal 2021 financial guidance at this time citing the persistent uncertainty with respect to the COVID-19 pandemic.
Patterson Companies ended first-quarter fiscal 2021 on a strong note, wherein both earnings and revenues beat the consensus mark. However, the company’s Dental and Animal Health segments displayed a dismal performance in the reported quarter. The company also witnessed contraction in gross margin in the quarter under review.
Nonetheless, prudent cost savings approach and operational execution worked well for the stock. Also, despite ongoing market disruption resulting from the pandemic, the company’s Dental and Animal Health segments witnessed recovery. This was attributable to the improvement in year-over-year sales performance in each fiscal month throughout the fiscal first quarter.
Also, a broad spectrum of products cushions the company against economic downturns in the MedTech space. We believe that a diverse product portfolio, strong veterinary business prospects, accretive acquisitions and strategic partnerships are key catalysts.
Patterson Companies carries a Zacks Rank #3 (Hold).
Earnings of Other MedTech Majors at a Glance
Some better-ranked stocks in the broader medical space that have already announced their quarterly results are Thermo Fisher Scientific Inc. TMO, PerkinElmer, Inc. PKI and West Pharmaceutical Services, Inc. WST. While both PerkinElmer and West Pharmaceuticals sport a Zacks Rank of 1 (Strong Buy), Thermo Fisher carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
PerkinElmer reported second-quarter 2020 adjusted EPS of $1.57, which surpassed the Zacks Consensus Estimate by 68.8%. Revenues of $811.7 million outpaced the consensus mark by 1.3%.
West Pharmaceuticals reported second-quarter 2020 adjusted EPS of $1.25, outpacing the Zacks Consensus Estimate of 91 cents. Revenues of $527.2 million surpassed the consensus mark by 6.9%.
Thermo Fisher reported second-quarter 2020 adjusted EPS of $3.89, beating the Zacks Consensus Estimate by 45.7%. Revenues of $6.92 billion surpassed the consensus mark by 0.1%.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PerkinElmer, Inc. (PKI) : Free Stock Analysis Report
Patterson Companies, Inc. (PDCO) : Free Stock Analysis Report
Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report
West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research